Hematology:Myelofibrosis — Bone marrow transplantation. Treatment abroad
Myelofibrosis is a malignant blood disorder caused by stem cell mutations. This disorder causes a gradual replacement of normal bone marrow tissue with scar (fibrous) tissues. The tumor symptoms are easily confused with other pathologies, and thus a leading role in its diagnostics is played by laboratory and instrumental research methods.
The diagnosis is established by a hematologist or oncologist. During the first visit, the physician clarifies complaints, conducts clinical examination and collects the case history. If there is suspicion for myelofibrosis, the patient is prescribed:
- Complete blood count. The patients show changes in the size and shape of blood cells (anisotropy and poikilocytosis). The leukocyte content of the blood increases, and so does the platelet content at the later stages of the disease.
- Blood chemistry. It helps diagnosing the liver dysfunctions accompanying the myelofibrosis development.
- Cytogenetic analysis. Various staining techniques allow detecting mutations associated with malignant disease in the genome of hematopoietic cells.
- Abdominal ultrasound. Populating the liver and spleen, cancerous cells provoke an increase in their size.
- Comprehensive CT/MRI. With the help of visual diagnostic methods, the physician determines the extent to which the tumor process spread throughout the body.
- Bone marrow aspiration biopsy (ilium wing punch biopsy). A sample of the patient’s bone marrow is taken and sent for histological examination. According to the test findings, the tumor nature is established.
In the course of diagnostics, the symptomatic therapy is administered, which helps alleviating the disease symptoms. According to the test findings, the physician establishes an accurate diagnosis and provides recommendations for further treatment.Hide